The Randomized Olmesartan and Diabetes Microalbuminuria Prevention ( ROADMAP ) study showed that @ mg Olmesartan medoxomil ( OM ) versus placebo delayed microalbuminuria onset in patients with type @ diabetes and normoalbuminuria .